Researchers at Cornell University have achieved what reproductive scientists have chased for decades: a nonhormonal, reversible method of shutting down male sperm production entirely and turning it back on.
The findings, published April 7 in the Proceedings of the National Academy of Sciences, are a proof-of-principle that rewrites what male contraception could look like in the near future.
The six-year study used a compound called JQ1, a small molecule inhibitor originally developed to study cancer and inflammatory diseases, to temporarily halt meiosis the biological process that produces sperm without causing lasting harm. Once the treatment stopped, sperm production fully recovered, the mice became fertile again, and their offspring were healthy.
Crucially, the researchers deliberately avoided targeting the spermatogonial stem cells the upstream source of sperm because damaging those would make fertility impossible to restore. “If you kill those, a man will never become fertile again,” said Paula Cohen, professor of genetics and director of the Cornell Reproductive Sciences Center.
The research was supported by the Gates Foundation, which has deep commitments across sub-Saharan Africa, including Rwanda. That funding signal alone suggests this science is not being developed only with Western consumers in mind.
If developed for human use, the contraceptive could be delivered as an injection every three months or possibly as a patch delivery formats that map directly onto how healthcare already reaches people in Rwanda, where injectable contraceptives are the most widely used modern method.
Rwanda has done more than almost any country in Africa to build contraceptive access at scale. Contraceptive use jumped from 17% to 53% in just one decade, from 2005 to 2015 a rise built on government will, community health workers, and a deliberate push to decentralize services. But the program has remained almost entirely female-led.
According to UNFPA Rwanda data, vasectomy is a hard sell among men, with most reluctant to engage in family planning at all a gap that has consistently pushed the burden of contraception onto women. Rwanda has committed under FP2030 to reaching 65% modern contraceptive coverage by 2030, and the unmet demand won’t close without male participation.
A reversible, needle-based male option familiar in form, no surgery, no permanent commitment is exactly the kind of tool that could shift that dynamic.
Cohen and her team plan to launch a company within the next two years to continue developing the method, and are already working on three additional gene targets they believe could more completely halt meiosis with even fewer side effects. JQ1 itself is not the final product its neurological side effects rule that out, But it proved the concept works.
The path from mouse study to human trial to approved product typically takes 10 to 15 years, which means African health systems have time to prepare and advocate to be part of this pipeline early, before pricing and distribution decisions get locked in by wealthy-market priorities.
About the Author
